Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels.

Kuryshev YA, Bruening-Wright A, Brown AM, Kirsch GE.

J Cardiovasc Pharmacol. 2010 Oct;56(4):420-30. doi: 10.1097/FJC.0b013e3181f1d21b.

PMID:
20930594
2.

QT interval prolongation and cardiac risk assessment for novel drugs.

Picard S, Lacroix P.

Curr Opin Investig Drugs. 2003 Mar;4(3):303-8. Review.

PMID:
12735231
3.
4.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.

Cardiovasc Res. 2003 Apr 1;58(1):32-45. Review.

PMID:
12667944
5.

Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.

Zünkler BJ.

Pharmacol Ther. 2006 Oct;112(1):12-37. Epub 2006 May 2. Review.

PMID:
16647758
6.

HERG block, QT liability and sudden cardiac death.

Brown AM.

Novartis Found Symp. 2005;266:118-31; discussion 131-5, 155-8. Review.

PMID:
16050265
7.
8.

Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.

Witchel HJ, Hancox JC.

Clin Exp Pharmacol Physiol. 2000 Oct;27(10):753-66. Review.

PMID:
11022966
9.
10.

Acquired QT interval prolongation and HERG: implications for drug discovery and development.

Finlayson K, Witchel HJ, McCulloch J, Sharkey J.

Eur J Pharmacol. 2004 Oct 1;500(1-3):129-42. Review.

PMID:
15464027
11.

Computational biology in the study of cardiac ion channels and cell electrophysiology.

Rudy Y, Silva JR.

Q Rev Biophys. 2006 Feb;39(1):57-116. Epub 2006 Jul 19. Review.

12.

[Short QT syndrome as an inherited condition].

Møller DV, Hedley PL, Olesen M, Kanters J, Svendsen JH, Christiansen M.

Ugeskr Laeger. 2011 Feb 7;173(6):420-4. Review. Danish.

PMID:
21299935
13.

Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.

Kraushaar U, Meyer T, Hess D, Gepstein L, Mummery CL, Braam SR, Guenther E.

Expert Opin Drug Saf. 2012 Mar;11(2):285-98. doi: 10.1517/14740338.2012.639358. Epub 2011 Nov 22. Review.

PMID:
22103746
14.

Ion channel macromolecular complexes in cardiomyocytes: roles in sudden cardiac death.

Abriel H, Rougier JS, Jalife J.

Circ Res. 2015 Jun 5;116(12):1971-88. doi: 10.1161/CIRCRESAHA.116.305017. Review.

15.

Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.

Titier K, Girodet PO, Verdoux H, Molimard M, Bégaud B, Haverkamp W, Lader M, Moore N.

Drug Saf. 2005;28(1):35-51. Review.

PMID:
15649104
16.

Control of cardiac repolarization by phosphoinositide 3-kinase signaling to ion channels.

Ballou LM, Lin RZ, Cohen IS.

Circ Res. 2015 Jan 2;116(1):127-37. doi: 10.1161/CIRCRESAHA.116.303975. Review.

17.

High throughput functional screening of an ion channel library for drug safety and efficacy.

Brown AM.

Eur Biophys J. 2009 Mar;38(3):273-8. doi: 10.1007/s00249-008-0356-2. Epub 2008 Aug 2. Review.

PMID:
18677468
18.

Blockade of cardiac potassium and other channels by antihistamines.

Delpón E, Valenzuela C, Tamargo J.

Drug Saf. 1999;21 Suppl 1:11-8; discussion 81-7. Review.

PMID:
10597864
19.

Ion channels in analgesia research.

Wood JN.

Handb Exp Pharmacol. 2007;(177):329-58. Review.

20.

Forward trafficking of ion channels: what the clinician needs to know.

Smyth JW, Shaw RM.

Heart Rhythm. 2010 Aug;7(8):1135-40. doi: 10.1016/j.hrthm.2010.05.030. Epub 2010 May 25. Review.

Supplemental Content

Support Center